Lumefantrine for Plasmodium vivax Malaria
Yes, artemether-lumefantrine (AL) can be used to treat P. vivax malaria, though chloroquine remains first-line in most settings; AL is specifically recommended for chloroquine-resistant P. vivax from Papua New Guinea, Indonesia, and Sabah, and must be combined with primaquine for radical cure. 1
Treatment Algorithm for P. vivax
First-Line Treatment (Chloroquine-Sensitive Areas)
- Chloroquine is the preferred drug of choice for uncomplicated P. vivax malaria 1
- Dosing: 1000 mg salt initially, then 500 mg at 6,24, and 48 hours (total 25 mg base/kg over 3 days) 1
- Always add primaquine 30 mg base daily for 14 days for radical cure of hypnozoites 1
When to Use Artemether-Lumefantrine Instead
Use AL for P. vivax if:
- Patient acquired infection from chloroquine-resistant areas (Papua New Guinea, Indonesia, Sabah) where CQ failure exceeds 10% 1
- Co-endemic areas where AL is already used routinely for P. falciparum and species differentiation is not performed 2
- Chloroquine is contraindicated or unavailable
AL Dosing for P. vivax
- Standard 6-dose regimen over 3 days (same as for P. falciparum) 1
35 kg: 4 tablets at H0, H8, H36, H48, H60, H72 (24 tablets total)
- Must be taken with fatty meal or drink for adequate absorption 1
- Must add primaquine for radical cure 1
Critical Caveats
Efficacy Considerations
- AL shows 100% parasite clearance by day 3 but has higher recurrence rates than chloroquine at day 28 when primaquine is not given 3, 4
- The recurrence rate at day 42 is significantly higher with AL (44%) versus dihydroartemisinin-piperaquine (9.3%) due to lumefantrine's shorter half-life 3
- This difference becomes clinically irrelevant when primaquine is added for radical cure 1, 3
Important Limitations
- AL is only FDA/EMA registered for P. falciparum malaria - use for P. vivax is technically off-label in Europe 1
- WHO recommends ACTs for all non-falciparum species, but registration restrictions may limit availability 1
- The shorter post-treatment prophylaxis with AL (versus other ACTs) means more relapses if primaquine is omitted 3, 2
Primaquine is Essential
- Without primaquine, relapse rates are unacceptably high regardless of which blood-stage drug is used 1
- Test for G6PD deficiency before primaquine administration 1
- For G6PD deficiency (30-70% activity, non-Mediterranean variant): weekly primaquine 45 mg for 8 weeks 1
- Contraindicated in pregnancy 1
Drug Interactions
When patients are on efavirenz-containing HIV regimens, lumefantrine levels are significantly reduced 5 - consider alternative antimalarials in this population.
Comparative Efficacy Data
Studies show AL is effective for P. vivax with cure rates of:
- 100% efficacy in Sudan (day 28) 6
- 97% efficacy in Guyana when combined with primaquine 4
- Lower effectiveness (81%) versus chloroquine (92.5%) in Ethiopia, though evening doses were unsupervised 7
The key finding is that delaying P. vivax recurrence improves hemoglobin recovery - for every 5 days recurrence is delayed, hemoglobin increases by 0.13 g/dL 3. This supports using longer-acting ACTs or ensuring primaquine compliance.
Practical Recommendation
For most P. vivax cases: Use chloroquine + primaquine. Reserve AL + primaquine for confirmed chloroquine-resistant areas or when chloroquine is unavailable. The choice of blood-stage drug matters less than ensuring complete primaquine radical cure to prevent relapses and improve patient outcomes.